Based on these understandings, interventions for cancer immunotherapy should aim at enhancing NKG2D expression and signaling in effector cells, sustaining the highest levels of NKG2D ligands on tumor cell surface, and eliminating soluble NKG2D ligands. Here, KLRK1 is linked to cancer.